Comorbid sleep disorders among patients with epilepsy are linked to higher SUDEP risk scores and all-cause mortality.

The FDA has accepted Apnimed’s NDA for AD109 (aroxybutynin/atomoxetine), a potential first-in-class oral therapy for adults with obstructive sleep apnea.

The FDA has approved Leqembi Iqlik (lecanemab-irmb) subcutaneous weekly starting dose, enabling fully at-home treatment initiation for early Alzheimer disease.

Learn about notable updates that occurred in June 2026 for investigational products in development (not an inclusive list).

Initiating high-efficacy monoclonal antibody therapy before age 18 may reduce long-term disability in pediatric-onset multiple sclerosis.

High intake of ultra-processed foods is associated with an increased risk for cognitive impairment, particularly in adults younger than 60 years.

Hypertension control among people experiencing homelessness can be improved through field-based health care programs.

Older adults with a new prescription for a sedative have an increased risk for falls and adverse events in the 30 days after ...

The cognitive benefits of smoking cessation were greatest among individuals who gained no more than 5 kg after quitting, whereas greater weight gain was associated with loss of these benefits. Smoking ...

White matter disease detected on CT may indicate a higher risk for future stroke or dementia compared with disease detected only on MRI.

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics Lic ...